WO2006005462A3 - Diagnostics and therapeutics for diseases associated with tyrosine kinase wee 1 (wee1) - Google Patents

Diagnostics and therapeutics for diseases associated with tyrosine kinase wee 1 (wee1) Download PDF

Info

Publication number
WO2006005462A3
WO2006005462A3 PCT/EP2005/007147 EP2005007147W WO2006005462A3 WO 2006005462 A3 WO2006005462 A3 WO 2006005462A3 EP 2005007147 W EP2005007147 W EP 2005007147W WO 2006005462 A3 WO2006005462 A3 WO 2006005462A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
wee1
wee
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2005/007147
Other languages
French (fr)
Other versions
WO2006005462A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2006005462A2 publication Critical patent/WO2006005462A2/en
Publication of WO2006005462A3 publication Critical patent/WO2006005462A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a human Wee1 which is associated with cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, gastroenterological diseases, cancer, e.g. breast cancer, inflammation, hematological diseases, respiratory diseases and urological diseases e.g. prostate benign prostatic hyperplasia. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of Wee1 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/007147 2004-07-15 2005-07-02 Diagnostics and therapeutics for diseases associated with tyrosine kinase wee 1 (wee1) WO2006005462A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04016634 2004-07-15
EP04016634.0 2004-07-15

Publications (2)

Publication Number Publication Date
WO2006005462A2 WO2006005462A2 (en) 2006-01-19
WO2006005462A3 true WO2006005462A3 (en) 2006-06-15

Family

ID=34972028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007147 WO2006005462A2 (en) 2004-07-15 2005-07-02 Diagnostics and therapeutics for diseases associated with tyrosine kinase wee 1 (wee1)

Country Status (1)

Country Link
WO (1) WO2006005462A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076539A2 (en) * 2007-12-11 2009-06-18 The Scripps Research Institute Modulation of protein degradation and uses thereof
WO2014188201A2 (en) * 2013-05-22 2014-11-27 Cancer Research Technology Limited Treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003038088A1 (en) * 2001-11-02 2003-05-08 Fujisawa Pharmaceutical Co., Ltd. Molecular diagnosis method for multiple myeloma
US6733966B1 (en) * 1997-06-04 2004-05-11 Rijksuniversiteit Te Leiden Diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733966B1 (en) * 1997-06-04 2004-05-11 Rijksuniversiteit Te Leiden Diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
WO2003038088A1 (en) * 2001-11-02 2003-05-08 Fujisawa Pharmaceutical Co., Ltd. Molecular diagnosis method for multiple myeloma

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 2002, XP002345349, retrieved from EBI Database accession no. CA487773 *
EGLAND KRISTI A ET AL: "Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 100, no. 3, 4 February 2003 (2003-02-04), pages 1099 - 1104, XP002308215, ISSN: 0027-8424 *
YARDEN RONIT I ET AL: "BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage.", NATURE GENETICS. MAR 2002, vol. 30, no. 3, March 2002 (2002-03-01), pages 285 - 289, XP002345284, ISSN: 1061-4036 *
YOSHIDA T ET AL: "The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer.", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO. FEB 2004, vol. 15, no. 2, February 2004 (2004-02-01), pages 252 - 256, XP002345285, ISSN: 0923-7534 *

Also Published As

Publication number Publication date
WO2006005462A2 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005078117A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 6 (klk6)
WO2006005462A3 (en) Diagnostics and therapeutics for diseases associated with tyrosine kinase wee 1 (wee1)
WO2005022146A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 13 (klk13)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2004097358A3 (en) Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2005075662A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
WO2005090994A3 (en) Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1)
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
WO2005083105A3 (en) Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b)
WO2005031346A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor1 (adipor1)
WO2005095953A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6)
WO2005095631A3 (en) Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 alpha (mlk4 alpha)
WO2006013014A3 (en) Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2006013013A3 (en) Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
WO2005101011A3 (en) Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase